Monday, April 02, 2012

Amgen and AstraZeneca Announce Collaboration to Jointly Develop and Commercialize Clinical-Stage Inflammation Portfolio

Collaboration Comprises Five Monoclonal Antibodies

Brodalumab (AMG 827) Phase 3 Trial Planned in 2012

THOUSAND OAKS, Calif. and LONDON, April 2, 2012 /PRNewswire/—Amgen (NASDAQ:AMGN) and AstraZeneca Plc, today announced an agreement to jointly develop and commercialize five monoclonal antibodies from Amgen’s clinical inflammation portfolio (AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827)).

Read the rest of this entry

Posted in Press Releases

Wednesday, March 28, 2012

Amgen Announces Phase 2 Study Results for Brodalumab in Moderate to Severe Plaque Psoriasis Published in the New England Journal of Medicine

Brodalumab Moving Into Phase 3 for Moderate to Severe Psoriasis

THOUSAND OAKS, Calif., March 28, 2012 /PRNewswire/—Amgen (NASDAQ:AMGN) announced today that results from a Phase 2 trial evaluating the safety and efficacy of brodalumab (formerly AMG 827) in 198 patients with moderate to severe plaque psoriasis were published in the New England Journal of Medicine. The 12-week, dose-ranging study achieved its primary endpoint with the mean percentage improvement in psoriasis area and severity index (PASI) score higher in all brodalumab groups compared to placebo (p<0.001).  Brodalumab is a human monoclonal antibody that selectively binds to and blocks signaling via the interleukin-17 (IL-17) receptor, thereby stopping the binding of several IL-17 family members associated with psoriasis. The majority of subjects treated with brodalumab 210 mg every other week achieved total clearance of their skin disease (PASI 100 of 62 percent).

Read the rest of this entry

Posted in Press Releases

Sunday, March 25, 2012

Amgen's PCSK9 Inhibitor Reduced LDL Cholesterol up to 81 Percent in Phase 1b Study

Robust AMG 145 Phase 2 Program Expected to Deliver Results in 2012

THOUSAND OAKS, Calif., March 25, 2012 /PRNewswire/—Amgen (NASDAQ:AMGN) announced today positive results from a Phase 1b clinical study of AMG 145, an investigational PCSK9 inhibitor, in patients with high cholesterol who were taking statins. The study demonstrated that multiple doses of AMG 145 significantly reduced serum low density lipoprotein cholesterol (LDL-C), also known as "bad" cholesterol, by up to 81 percent versus placebo (maximum reduction) in subjects on low to moderate doses of statins (p<0.001).  The cholesterol lowering effects of AMG 145 were similar among patients on high doses of statins (80 mg atorvastatin and 40 mg rosuvastatin) and patients on low to moderate doses of statins. No deaths or serious adverse events (AEs) were reported in the study. Full results of the study were presented for the first time today in an oral session at the American College of Cardiology Scientific Session in Chicago.  (Abstract # 923-4)

Read the rest of this entry

Posted in Press Releases

Thursday, March 15, 2012

Amgen Announces 2012 Second Quarter Dividend

THOUSAND OAKS, Calif., March 15, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.36 per share dividend for the second quarter of 2012. The dividend will be paid on June 7, 2012, to all stockholders of record as of the close of business on May 16, 2012.

Read the rest of this entry

Posted in Press Releases

Wednesday, March 07, 2012

Amgen Completes Tender Offer for Outstanding Shares of Micromet, Inc.

THOUSAND OAKS, Calif., March 7, 2012 /PRNewswire/ -- Amgen Inc.  ("Amgen") (NASDAQ:AMGN) announced today the expiration of the subsequent offering period of the tender offer (the "Offer") by a wholly owned subsidiary, "Merger Sub," to acquire all outstanding shares of common stock of Micromet, Inc. ("Micromet") (NASDAQ:MITI) for $11.00 per share in cash.  The subsequent offering period expired at 12:00 midnight, New York City time, at the end of Tuesday, March 6, 2012. 

Read the rest of this entry

Posted in Press Releases